MCID: BRS015
MIFTS: 37

Breast Medullary Carcinoma malady

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Breast Medullary Carcinoma

Aliases & Descriptions for Breast Medullary Carcinoma:

Name: Breast Medullary Carcinoma 12 14
Medullary Breast Carcinoma with Lymphoid Stroma 12
Medullary Carcinoma of Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5605
NCIt 47 C9119
UMLS 69 C0860580

Summaries for Breast Medullary Carcinoma

MalaCards based summary : Breast Medullary Carcinoma, also known as medullary breast carcinoma with lymphoid stroma, is related to skeletal muscle cancer and macrogyria, pseudobulbar palsy and mental retardation. An important gene associated with Breast Medullary Carcinoma is GZMB (Granzyme B), and among its related pathways/superpathways are Glioma and Development HGF signaling pathway. The drugs Estradiol and Vinblastine have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Breast Medullary Carcinoma

Diseases related to Breast Medullary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 120)
id Related Disease Score Top Affiliating Genes
1 skeletal muscle cancer 10.2 FASLG GZMB
2 macrogyria, pseudobulbar palsy and mental retardation 10.2 FASLG GZMB
3 malignant teratoma 10.2 FASLG GZMB
4 adenylosuccinase lyase deficiency 10.2 FASLG GZMB
5 venezuelan hemorrhagic fever 10.2 FASLG GZMB
6 mixed cell type cancer 10.2 FASLG GZMB
7 acute myeloid leukemia with recurrent genetic anomaly 10.1 FASLG GZMB
8 hereditary breast ovarian cancer 10.1 ERBB2 ESR1
9 substance abuse 10.1 ERBB2 ESR1
10 kunjin encephalitis 10.1 BRCA1 ERBB2
11 lung clear cell-sugar-tumor 10.1 BRCA1 ERBB2
12 hyperaldosteronism, familial, type ii 10.1 FASLG GZMB
13 bladder colloid adenocarcinoma 10.1 BRCA1 ERBB2
14 nemaline myopathy 8, autosomal recessive 10.1 BRCA1 ERBB2
15 psoriasis susceptibility 1 10.0 FASLG GZMB
16 mouth disease 10.0 ERBB2 PGR
17 bartholin's gland benign neoplasm 10.0 ESR1 PGR
18 cardiovascular organ benign neoplasm 10.0 ESR1 PGR
19 appendix leiomyoma 10.0 ESR1 PGR
20 bronchus adenoma 10.0 ESR1 PGR
21 ovarian benign neoplasm 10.0 ESR1 PGR
22 plexiform neurofibroma 10.0 ESR1 PGR
23 periodontosis 10.0 FASLG GZMB
24 paranasal sinus disease 10.0 ESR1 PGR
25 mucoepidermoid thyroid carcinoma 10.0 ERBB2 PGR
26 deafness, autosomal recessive 21 10.0 ESR1 PGR
27 triple-receptor negative breast cancer 10.0 ERBB2 PGR
28 skin sarcoma 10.0 ERBB2 PGR
29 atypical lipomatous tumor 10.0 ESR1 PGR
30 pediatric intraocular retinoblastoma 10.0 ESR1 PGR
31 congenital disorder of glycosylation, type ic 10.0 ESR1 PGR
32 intestinal perforation 10.0 ESR1 PGR
33 perlman syndrome 10.0 ESR1 PGR
34 bladder adenocarcinoma 10.0 ESR1 PGR
35 anal neuroendocrine tumor 10.0 ESR1 PGR
36 osteogenesis imperfecta 10.0 ESR1 PGR
37 intestinal neuroendocrine benign tumor 10.0 ERBB2 PGR
38 vulva basal cell carcinoma 10.0 ESR1 PGR
39 vaginal adenosarcoma 10.0 ESR1 PGR
40 intraneural perineurioma 10.0 ESR1 PGR
41 middle ear adenocarcinoma 10.0 ESR1 PGR
42 basaloid squamous cell carcinoma 10.0 ERBB2 PGR
43 infiltrating angiolipoma 10.0 ERBB2 PGR
44 acute thyroiditis 10.0 ESR1 PGR
45 fallopian tube adenocarcinoma 10.0 ERBB2 ESR1
46 mucoepidermoid esophageal carcinoma 10.0 ESR1 PGR
47 perinatal jaundice due to hepatocellular damage 10.0 ESR1 PGR
48 deafness, autosomal recessive 74 10.0 ESR1 PGR
49 adult neuronal ceroid lipofuscinosis 10.0 ESR1 PGR
50 vulvar alveolar soft part sarcoma 10.0 ESR1 PGR

Graphical network of the top 20 diseases related to Breast Medullary Carcinoma:



Diseases related to Breast Medullary Carcinoma

Symptoms & Phenotypes for Breast Medullary Carcinoma

MGI Mouse Phenotypes related to Breast Medullary Carcinoma:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.89 BRCA1 ERBB2 ESR1 FASLG PGR
2 endocrine/exocrine gland MP:0005379 9.85 BRCA1 ERBB2 ESR1 FASLG PGR
3 integument MP:0010771 9.83 BRCA1 ERBB2 ESR1 FASLG PGR
4 digestive/alimentary MP:0005381 9.78 BRCA1 ERBB2 ESR1 FASLG
5 neoplasm MP:0002006 9.72 BRCA1 ERBB2 ESR1 FASLG PGR
6 limbs/digits/tail MP:0005371 9.71 BRCA1 ERBB2 ESR1 PGR
7 muscle MP:0005369 9.67 BRCA1 ERBB2 ESR1 PGR
8 normal MP:0002873 9.65 ERBB2 ESR1 FASLG PGR BRCA1
9 reproductive system MP:0005389 9.55 BRCA1 ERBB2 ESR1 FASLG PGR
10 respiratory system MP:0005388 9.26 ERBB2 ESR1 FASLG BRCA1
11 skeleton MP:0005390 9.02 BRCA1 ERBB2 ESR1 FASLG PGR

Drugs & Therapeutics for Breast Medullary Carcinoma

Drugs for Breast Medullary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
2
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
3
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
4
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
5
Carboplatin Approved Phase 2, Phase 3, Phase 1 41575-94-4 10339178 498142 38904
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
7
Trastuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 180288-69-1 9903
8
Fulvestrant Approved, Investigational Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
9
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
10
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
11
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
12
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
13
Paclitaxel Approved, Vet_approved Phase 2, Phase 3, Phase 1 33069-62-4 36314
14
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
15
Letrozole Approved, Investigational Phase 3,Phase 2,Phase 1 112809-51-5 3902
16
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
17
Metformin Approved Phase 3 657-24-9 14219 4091
18
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
19
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
20
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
21
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
22
Pertuzumab Approved Phase 3,Phase 2 145040-37-5, 380610-27-5 2540
23
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
24
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
25
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
26
Doxil Approved June 1999 Phase 2, Phase 3, Phase 1 31703
27 Estradiol valerate Phase 3,Phase 2,Phase 1 979-32-8
28 Alkylating Agents Phase 3,Phase 2,Phase 1
29 Selective Estrogen Receptor Modulators Phase 3,Phase 2
30 Topoisomerase Inhibitors Phase 2, Phase 3, Phase 1
31 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
32 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1
33 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
35 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
36 Estradiol 17 beta-cypionate Phase 3,Phase 2,Phase 1
37 Estradiol 3-benzoate Phase 3,Phase 2,Phase 1
38 Estrogen Antagonists Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 2, Phase 3, Phase 1
40 Estrogen Receptor Antagonists Phase 3,Phase 2,Phase 1
41 Estrogen Receptor Modulators Phase 3,Phase 2
42 Estrogens Phase 3,Phase 2,Phase 1
43 Polyestradiol phosphate Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 Antimetabolites Phase 3,Phase 2,Phase 1
46 Antibiotics, Antitubercular Phase 2, Phase 3, Phase 1
47 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 167)
id Name Status NCT ID Phase
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy Completed NCT00616135 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC) Unknown status NCT01126138 Phase 3
5 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer Completed NCT01508546 Phase 3
8 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
9 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3
10 Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 Recruiting NCT02620280 Phase 3
11 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
12 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3
13 Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer Recruiting NCT01905046 Phase 3
14 Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Recruiting NCT02221999 Phase 2, Phase 3
15 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Recruiting NCT02125344 Phase 3
16 Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3
17 Oxybutynin Chloride in Managing Hot Flashes Recruiting NCT02961790 Phase 3
18 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
19 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
20 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Active, not recruiting NCT00321048 Phase 3
21 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3
22 "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Unknown status NCT01641406 Phase 2
23 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
24 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2
25 Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Completed NCT01023477 Phase 1, Phase 2
26 Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer Completed NCT00002873 Phase 1, Phase 2
27 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast Completed NCT03002766 Phase 2
28 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2
29 Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer Completed NCT00416403 Phase 2
30 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor Completed NCT01372618 Phase 2
31 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer Completed NCT00106002 Phase 2
32 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer Completed NCT00182793 Phase 2
33 Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Completed NCT02199418 Phase 2
34 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2
35 Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery Recruiting NCT02617082 Phase 2
36 Clinical Outcome of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast Recruiting NCT02897700 Phase 1, Phase 2
37 Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer Recruiting NCT01891357 Phase 2
38 Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer Recruiting NCT02636582 Phase 2
39 Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery Recruiting NCT02694809 Phase 2
40 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Recruiting NCT02540330 Phase 2
41 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Recruiting NCT02779855 Phase 1, Phase 2
42 G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Recruiting NCT02983071 Phase 1, Phase 2
43 Single Fraction Intraoperative Radiotherapy Recruiting NCT01688388 Phase 1, Phase 2
44 Radiation Therapy in Treating Women With Early Stage Breast Cancer Recruiting NCT00909909 Phase 2
45 Denosumab as an add-on Neoadjuvant Treatment (GeparX) Recruiting NCT02682693 Phase 2
46 Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery Recruiting NCT02526498 Phase 2
47 Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Recruiting NCT02314156 Phase 2
48 Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE) Recruiting NCT02576431 Phase 2
49 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
50 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Active, not recruiting NCT01237457 Phase 2

Search NIH Clinical Center for Breast Medullary Carcinoma

Genetic Tests for Breast Medullary Carcinoma

Anatomical Context for Breast Medullary Carcinoma

MalaCards organs/tissues related to Breast Medullary Carcinoma:

39
Breast

Publications for Breast Medullary Carcinoma

Articles related to Breast Medullary Carcinoma:

id Title Authors Year
1
Immunoglobulin repertoire of B lymphocytes infiltrating breast medullary carcinoma. ( 15156099 )
2003
2
A scFv phage display mini library generated from the immunoglobulin repertoire of breast medullary carcinoma infiltrating B lymphocytes. ( 11360824 )
2000
3
Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. ( 10065736 )
1999
4
E-cadherin and beta-catenin expression in breast medullary carcinomas. ( 10402239 )
1999

Variations for Breast Medullary Carcinoma

Cosmic variations for Breast Medullary Carcinoma:

9 (show all 19)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM763 PIK3CA breast,NS,carcinoma,medullary c.1633G>A p.E545K 12
2 COSM775 PIK3CA breast,NS,carcinoma,medullary c.3140A>G p.H1047R 12
3 COSM10742 TP53 breast,NS,carcinoma,medullary carcinoma c.578A>G p.H193R 11
4 COSM10758 TP53 breast,NS,carcinoma,medullary carcinoma c.659A>G p.Y220C 11
5 COSM10662 TP53 breast,NS,carcinoma,medullary carcinoma c.743G>A p.R248Q 11
6 COSM10893 TP53 breast,NS,carcinoma,medullary carcinoma c.824G>A p.C275Y 11
7 COSM11089 TP53 breast,NS,carcinoma,medullary carcinoma c.584T>C p.I195T 11
8 COSM10648 TP53 breast,NS,carcinoma,medullary carcinoma c.524G>A p.R175H 11
9 COSM11286 TP53 breast,NS,carcinoma,medullary carcinoma c.1015G>T p.E339* 11
10 COSM10731 TP53 breast,NS,carcinoma,medullary carcinoma c.707A>G p.Y236C 11
11 COSM44687 TP53 breast,NS,carcinoma,medullary carcinoma c.379T>C p.S127P 11
12 COSM11148 TP53 breast,NS,carcinoma,medullary carcinoma c.476C>T p.A159V 11
13 COSM10654 TP53 breast,NS,carcinoma,medullary carcinoma c.637C>T p.R213* 11
14 COSM10728 TP53 breast,NS,carcinoma,medullary carcinoma c.839G>A p.R280K 11
15 COSM43947 TP53 breast,NS,carcinoma,medullary carcinoma c.614A>G p.Y205C 11
16 COSM10726 TP53 breast,NS,carcinoma,medullary carcinoma c.856G>A p.E286K 11
17 COSM10646 TP53 breast,NS,carcinoma,medullary carcinoma c.725G>A p.C242Y 11
18 COSM10667 TP53 breast,NS,carcinoma,medullary carcinoma c.646G>A p.V216M 11
19 COSM10834 TP53 breast,NS,carcinoma,medullary carcinoma c.711G>A p.M237I 11

Expression for Breast Medullary Carcinoma

Search GEO for disease gene expression data for Breast Medullary Carcinoma.

Pathways for Breast Medullary Carcinoma

Pathways related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 BRCA1 ERBB2 ESR1 PGR
2
Show member pathways
12.38 ERBB2 ESR1 FASLG
3 11.74 ERBB2 ESR1 FASLG
4
Show member pathways
11.58 BRCA1 ESR1 PGR
5 11.31 BRCA1 ERBB2
6
Show member pathways
11.26 FASLG GZMB
7 11.24 BRCA1 ERBB2
8
Show member pathways
11.17 ERBB2 ESR1 PGR
9 11.14 BRCA1 FASLG
10
Show member pathways
11.07 BRCA1 ESR1
11
Show member pathways
10.97 FASLG GZMB
12 10.66 BRCA1 ERBB2 FASLG

GO Terms for Breast Medullary Carcinoma

Biological processes related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.55 BRCA1 ERBB2 ESR1 FASLG PGR
2 transcription, DNA-templated GO:0006351 9.35 BRCA1 ERBB2 ESR1 FASLG PGR
3 response to estrogen GO:0043627 9.32 BRCA1 ESR1
4 steroid hormone mediated signaling pathway GO:0043401 9.26 ESR1 PGR
5 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 8.62 BRCA1 FASLG

Molecular functions related to Breast Medullary Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.33 BRCA1 ESR1 PGR
2 ATPase binding GO:0051117 9.32 ESR1 PGR
3 steroid hormone receptor activity GO:0003707 9.26 ESR1 PGR
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 8.96 ESR1 PGR
5 steroid binding GO:0005496 8.62 ESR1 PGR

Sources for Breast Medullary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....